Crossmark

RFFL-mediated protein quality control limits functional rescue of TRID-CFTR modulator combination therapy for cystic fibrosis nonsense mutations

Published Online: 2026-02-21

Authors

Tateishi, Hazuki

Doi, Yukako

Kamada, Yuka

Okiyoneda, Tsukasa https://orcid.org/0000-0002-5175-2224
Funding

Funding for this research was provided by:

JSPS KAKENHI (21H00294)

JSPS KAKENHI (23K23840)

JSPS KAKENHI (25K02231)

Takeda Science Foundation

Kwansei Gakuin University (an Individual Special Research Subsidy with grants)
License Information

Text and Data Mining valid from 2026-02-21

Version of Record valid from 2026-02-25
More Information

Article History

Received: 11 November 2025

Revised: 14 January 2026

Accepted: 4 February 2026

First Online: 21 February 2026

Declarations

:

: Not applicable.

: All authors have consented to the publication of this work.

: All authors declare no competing interests.

: During the preparation of this work the authors used ChatGPT in order to improve language and readability. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.

Document is current